TimesSquare Capital Global Health Care Q1 2024 Commentary [Seeking Alpha]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Seeking Alpha
Large Cap Health Care underperformed the broader market with MSCI World Health Care returning 7.66% vs. 9.01% from MSCI World. While capital markets remain tight, reducing funding opportunities for the sector, we are encouraged to see continued robust M&A activity, as large cap balance sheets remain healthy. To Our Investors, Through the end of March 2024, the Fund's net performance was +2.76% QTD (+2.05% Net) and +39.87% (+25.91% Net) cumulative since inception (April 1, 2020). Although many equity markets slipped in January, they recovered over the next two months for a strong first quarter of 2024. Volatility remained low for the quarter. While growth equity indexes outshined value, Growth and Profitability had negative returns among global risk factors. Momentum was the dominant factor this quarter, indicating to us that this quarter's rally was not entirely driven by company fundamentals. Thus far in 2024, Health Care utilization rates have been strong, broadening intere
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- AHF Hails HRSA Stance on J&J's Illegal Attack on 340B Program [Yahoo! Finance]Yahoo! Finance
- CARVYKTI® ? (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line [Yahoo! Finance]Yahoo! Finance
- CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second linePR Newswire
- Bristol Cobenfy approval draws optimism from Street, though with caveats [Seeking Alpha]Seeking Alpha
- DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 7/17/24 - Beat
JNJ
Sec Filings
- 9/20/24 - Form 8-K
- 9/12/24 - Form 4
- 9/12/24 - Form 4
- JNJ's page on the SEC website